The MedRegen leadership partnered with a premier CDMO and invested heavily in developing a subcutaneous formulation of MRG-001 and is working towards producing an oral formulation.
The MedRegen leadership partnered with a premier CDMO and invested heavily in developing a subcutaneous formulation of MRG-001 and is working towards producing an oral formulation.
Optimized by Seraphinite Accelerator